Bath & Body Works (NYSE:BBWI) Price Target Raised to $22.00

Bath & Body Works (NYSE:BBWI) had its price objective raised by equities researchers at UBS Group from $17.00 to $22.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group‘s target price suggests a potential upside of 2.64% from the stock’s previous close.

BBWI has been the subject of several other reports. Citigroup raised Bath & Body Works from a “neutral” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Tuesday, August 18th. Wells Fargo & Company lifted their target price on Bath & Body Works from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Thursday, October 29th. JPMorgan Chase & Co. boosted their target price on Bath & Body Works from $22.00 to $24.00 and gave the company a “neutral” rating in a report on Tuesday, August 18th. Robert W. Baird cut their price target on Bath & Body Works from $25.00 to $23.00 and set a “neutral” rating for the company in a research note on Thursday, August 27th. Finally, Morgan Stanley cut their price target on Bath & Body Works from $22.00 to $20.00 and set an “equal weight” rating for the company in a research note on Thursday, August 27th. Four equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $22.53.

Bath & Body Works Trading Up 1.7%

NYSE:BBWI traded up $0.35 during midday trading on Friday, reaching $21.43. The company had a trading volume of 1,505,969 shares, compared to its average volume of 5,949,377. Bath & Body Works has a 12-month low of $14.27 and a 12-month high of $24.94. The firm has a market capitalization of $4.32 billion, a price-to-earnings ratio of 5.58, a PEG ratio of 1.09 and a beta of 1.31. The stock’s fifty day simple moving average is $19.16 and its 200-day simple moving average is $19.82.

Bath & Body Works (NYSE:BBWI) last posted its quarterly earnings results on Wednesday, August 26th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.24 by $0.38. Bath & Body Works had a net margin of 10.83% and a negative return on equity of 53.48%. The company had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter in the previous year, the business posted $0.30 EPS. The firm’s revenue was down 2.3% on a year-over-year basis. Bath & Body Works has set its Q3 2026 guidance at 0.070-0.120 EPS and its FY 2026 guidance at 2.600-2.800 EPS. As a group, sell-side analysts expect that Bath & Body Works will post 2.74 EPS for the current year.

Institutional Investors Weigh In On Bath & Body Works

A number of large investors have recently added to or reduced their stakes in the business. AlphaGrep UK Ltd grew its stake in shares of Bath & Body Works by 104.0% during the 3rd quarter. AlphaGrep UK Ltd now owns 32,381 shares of the company’s stock valued at $516,000 after purchasing an additional 16,510 shares during the period. Focus Advisor Solutions LLC lifted its stake in shares of Bath & Body Works by 13.8% in the 3rd quarter. Focus Advisor Solutions LLC now owns 28,139 shares of the company’s stock worth $448,000 after purchasing an additional 3,419 shares during the period. South Dakota Investment Council lifted its stake in shares of Bath & Body Works by 11.6% in the 3rd quarter. South Dakota Investment Council now owns 2,113,720 shares of the company’s stock worth $33,650,000 after purchasing an additional 219,832 shares during the period. Rothschild Investment LLC boosted its holdings in shares of Bath & Body Works by 12.5% in the third quarter. Rothschild Investment LLC now owns 7,570 shares of the company’s stock worth $121,000 after buying an additional 841 shares during the last quarter. Finally, Edgestream Partners L.P. purchased a new position in shares of Bath & Body Works in the third quarter worth approximately $2,586,000. 95.14% of the stock is owned by institutional investors and hedge funds.

Bath & Body Works Company Profile

Bath & Body Works, Inc. is a specialty retailer focused on personal care and home fragrance products. Its offerings include body lotions, soaps, fragrances, hand sanitizers, candles and other home-fragrance items, sold under the Bath & Body Works and White Barn brands. The company serves customers through its stores and e-commerce platform in the United States and Canada, as well as through international franchise, license and wholesale partners. Bath & Body Works traces its roots to a store launched in 1990.